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“எது நடந்தததோ, அது நன்றோகதே நடந்தது 
எது நடக்கிறததோ, அது நன்றோகதே நடக்கிறது 
எது நடக்க இருக்கிறததோ, அதுவும் நன்றோகதே நடக்கும் 
உன்னுடடயடத எடத இழந்தோய், எதற்கோக நீ அழுகிறோய்? 
எடத நீ ககோண்டுேந்தோய், அடத நீ இழப்பதற்கு? 
எடத நீ படடத்திருந்தோய், அது வீணோேதற்கு? 
எடத நீ எடுத்துக் ககோண்டோதயோ, அது இங்கிருந்தத எடுக்கப்பட்டது, 
எடத ககோடுத்தோதயோ, அது இங்தகதய ககோடுக்கப்பட்டது. 
எது இன்று உன்னுடடயததோ, அது நோடை மற்கறோருேருடடயதோகிறது, 
மற்கறோருநோை், அது தேகறோருேருடடயதோகும். 
இதுதே உலக நியதியும் எனது படடப்பின் சோரோம்சமோகும்” 
- பகவான் ஸ்ரீ கிருஷ்ணர் 
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ABSTRACT 
The main confirmed genetic risk factor for sporadic form of Alzheimer’s disease (AD) is 
apolipoprotein E (ApoE) ε4 allele (APOE4). ApoE protein aids in receptor ligand mediated 
transport, distribution and metabolism of fatty acids and cholesterol. However, the molecular 
mechanism of its contribution to the pathological events in AD is still highly obscure. Some 
reports implicate ApoE in amyloid-beta (Aβ) deposition in the brain, one of the main 
hallmarks of AD.  But there are no consensuses about how ApoE causes the accumulation of 
Aβ deposits. The main neuronal network that becomes severely affected in the course of AD 
and Lewy body dementia disorders (LBD) is the central cholinergic system, and the main 
available therapeutic options are cholinesterase inhibitors which prevents the degradation of 
cholinergic neurotransmitter, acetylcholine (ACh). However, it is unclear, why these 
particular neuronal populations are selectively affected in AD and LBD. In addition to the 
classical view of the cholinergic neurotransmission, extrasynaptic cholinergic signaling also 
plays a crucial role in the regulation of immune system. Although, it is not clear how ACh 
can reach and act on such non-neuronal cell population in the brain or in the peripheral 
organs.  
This thesis aimed to provide some insights in these unresolved issues. We found that APOE4 
gene dose-dependently was associated with the highest ApoE protein expression in 
cerebrospinal fluid (CSF) of dementia patients (AD and DLB). This finding was observed in 
two independent study cohorts. Correlation analyses between the CSF ApoE protein and 
clinical measures (various cognitive tests), paraclinical measures (cerebral glucose 
metabolism and Aβ load by positron emission tomography) and AD biomarkers (CSF Aβ and 
tau, etc) suggested that high levels of ApoE protein may act as one of the driving forces of the 
pathological events in AD and DLB. This thesis also examined a postulated genetic 
interaction between APOE4 and a certain genetic variant of the ACh-degrading enzyme, 
butyrylcholinesterase (BuChE), namely BCHE-K allele. This directed genetic analysis was 
then to some extent scrutinized at their protein expression levels. The findings indicated that 
in the absence of APOE4, BCHE-K was associated with the lowest CSF ApoE protein, and 
the slowest annual cognitive decline, suggestive of some protective effects by BCHE-K. In 
the presence of APOE4, this protective effect of BCHE-K was either insufficient or rather 
increased the negative impact of APOE4 on both CSF ApoE levels and the rate of annual 
cognitive decline in patients. 
Given that astrocytes, one of the key players of the immune system in the central nervous 
system are the main sources of ApoE and BuChE, this thesis also aimed at providing a 
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mechanistic understanding of the interplays between extrasynaptic cholinergic immune-
regulatory signaling, Aβ, ApoE and BuChE. 
In this context, our previous studies have provided evidence for APOE4 dependent molecular 
interaction between ApoE protein, Aβ and BuChE leading to formation of hyperactive 
BuChE-Aβ-ApoE complexes (BAβACs), which then accumulates in the brain, causing 
abnormal extrasynaptic ACh levels, astroglial dysfunction, altered Aβ clearance and 
aggregation in AD and DLB patients. Nonetheless, this hypothesis and the well-established 
cholinergic anti-inflammatory hypothesis faced a major dilemma, since ACh is a highly 
instable signaling molecule to be able to diffuse and act on cholinoceptive cells located far 
from the cholinergic synapses. This thesis provided a solution to this dilemma by providing 
for the first time, compelling evidence for the presence of ACh-synthesizing enzyme, choline 
acetyltransferase (ChAT) in human extracellular fluids, such as CSF and plasma. We showed 
that both lymphocytes and astrocytes might be the sources of soluble ChAT, as they were 
capable of acquiring cholinergic phenotype (expressing ChAT) on demand, and releasing 
ChAT into extracellular fluids. We showed that soluble ChAT was fully functional, and could 
maintain steady state ACh equilibrium in the presence of highly active ACh-degrading 
enzymes in CSF. Thus this thesis also provided for the first time evidence that astrocytes are 
cholinergic cells and hence might be an active part of the non-neuronal cholinergic network 
in the brain. In addition, the undertaking of this thesis led to development of a novel, sensitive 
integrated assay for sequential quantitative measurements of ChAT activity and protein levels 
in practically any biological fluid deemed to contain this enzyme. 
Conclusions and future perspectives: This thesis provided important insights into the complex 
interplays that are ongoing in vivo in the course of two major dementia disorders (AD and 
DLB) between several key genetic and/or molecular factors and cellular networks. This thesis 
also provided a novel research tool, facilitating future studies for reviewing the above 
hypothesis in the field of dementia as well as other neuroinflammatory disease such as 
multiple sclerosis, which this thesis has pointed out.  
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1 INTRODUCTION 
1.1 HISTORY OF DEMENTIA 
Dementia is an umbrella term that encompasses various memory disorders and mental 
disabilities, caused by the pathophysiological changes in the brain. Most of the dementia 
disorders are closely associated with age. Recorded evidence of dementia dates back 5000 – 
6000 years. During the period, 3000-1500 BC, dementia had been described as Cittanasa 
(Citta means mind, nasa means loss of) in Ayurveda, an ancient Indian medical system which 
is still in practice. Ayurveda also has records of the herbal medications available for the 
treatment of dementia [1], however these need to be re-evaluated for their efficacy, using the 
modern medical techniques. Ancient Egyptians, around 2000 BC, believed that aging could 
be accompanied by memory disorders [2]. The Greek and Roman philosophers and 
physicians during 7th century BC had also described the association of dementia with age [3]. 
In the modern age, Philippe Pinel (1745-1826), the founder of modern Psychiatry, gave a 
modern description of dementia [2].  
1.2 ALZHEIMER’S DISEASE  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder leading to severe 
disruption in normal brain structure and function [4]. It accounts for 60-80% of the all 
dementia cases and has become the sixth leading cause of death in the United States. 
According to an Alzheimer’s association report, by 2050, for every 33 seconds there will be a 
new individual developing AD in United States [5]. The first case of AD was described in 
1906 by Dr. Alois Alzheimer, a German physician [4]. Hence this disease has been named 
after him.  
The clinical symptoms of the disease include loss of memory, confusion, sleep disturbances, 
behavioral changes, language problems accompanied by difficulty in thinking, logical 
reasoning, visuospatial functions, sleeping and walking [6]. The typical disease pathology 
includes the presence of amyloid beta (Aβ) plaques and neurofibrillary tangles consisting of 
Tau protein deposits in the brain [7]. AD is also characterized by neuroinflammation, 
neuronal loss, synaptic dysfunction, cholinergic deficits, atrophy and low glucose metabolism 
in the brain [8-11]. Sometimes, the AD patients may also contain Lewy bodies in their brain 
[12] . However, which symptom occurs first and which follows next is still unclear. AD is 
more prevalent in women than men [13].   
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There are two major types of AD such as Familial AD (FAD) and Sporadic AD. (1) Familial 
AD is an early onset AD (EOAD) which accounts for about 15% of the total AD cases where 
the patients carry the risk genes for the disease due to their family history. FAD or EOAD is 
most common in patient groups who are <65 years of age. Three genes are closely associated 
with FAD - (i) amyloid precursor protein (APP) gene, (ii) presenilin 1 (PSEN1) and (iii) 
presenilin 2 (PSEN2), [14, 15]. (2) Sporadic AD or late onset AD (LOAD) occurs in people 
who do not have a family history of AD and most of the sporadic AD cases occurs at an age 
group >65 years. So far only Apolipoprotein E ε4 genotype (APOE4) and other epigenetic 
causes has been found to be closely associated with sporadic AD [15, 16]. 
1.3 DEMENTIA WITH LEWY BODIES 
Dementia with Lewy bodies (DLB) constitutes for about 10-25% of the total dementia cases 
worldwide (http://www.alz.org/dementia/dementia-with-Lewy-bodies-symptoms.asp). 
Although the presence of α-synuclein inclusions called Lewy bodies, in the brain was first 
discovered in early 1900s by Frederick H. Lewy, the presence of Lewy body-like pathology 
in a patient with AD was only first reported in 1976, by a Japanese psychiatrist and 
neuropathologist [17] and was later named as “Dementia with Lewy bodies”.  
The pathology of the disease includes the presence of α-synuclein inclusions called Lewy 
bodies in the brain along with amyloid plaques and neurofibrillary tangles leading to 
excessive neuronal loss in the brain stem nuclei, neocortical and limbic regions [18-20]. DLB 
patients experience more sleep related disturbances than AD patients [21]. They present co-
occurring AD and Parkinsonism, with symptoms such as motor dysfunctions, delusions, 
visual hallucinations, loss of synapses, cholinergic deficits, dopaminergic deficits, brain 
atrophy, low brain glucose metabolism and neuroinflammation which often leads to 
misdiagnosis of DLB most often as AD [22, 23].  Unlike AD, DLB is more common in men 
than women [24]. Whether, the genetic variant APOE4 plays an important role in DLB as it 
does in AD is not well known. 
1.4 PARKINSON’S DISEASE 
 The symptoms of Parkinson’s disease (PD) were first reported by Dr. James Parkinson in 
1817 in his essay on “shaking palsy” [25]. Later, this disease was named after him as 
Parkinson’s disease. It is one of the common types of neurodegenerative disorder, which 
mainly affects the motor functions causing rigidity, bradykinesia, tremor, slowness of 
movement and difficulty in walking [26]. The non-motor symptoms, such as depression, 
sleep disturbances, visuospatial deficits, often follow in the later stage of the disease, leading 
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to PD with dementia (PDD) [26, 27]. The PD pathology in brain is often characterized by the 
depletion of dopaminergic neurons and presence of Lewy bodies, especially in the mid brain 
region [28]. However, studies show that PD and PDD could also be accompanied by 
cholinergic deficits, synaptic dysfunction, Aβ plaques, Tau depositions and 
neuroinflammation [29]. The mutations in genes such as SNCA, LRRK2, VPS35, PINK1, 
DJ-1 and Parkin have been found to be associated with PD pathology [30].  
1.5 DEMENTIA DIAGNOSIS 
A diagnosis of dementia is based on detailed comprehensive assessment of findings from 
clinical history, physical examination and neuropsychological evaluation. This is often 
combined with neuroimaging and cerebrospinal fluid biomarker investigations. Important 
dementia risks, including cardiovascular abnormalities risk factors and senescence can be 
quantified using the CAIDE scale [31]. Dementia can be diagnosed using consensus criteria, 
such as the Diagnostic and Statistical Manual for Mental Disorders (DSM 5) criteria [32-34] 
or International Classification of Diseases -10 criteria (ICD-10,) which classify mental and 
behavioral disorders [35]. Many studies have employed different criteria for the specific 
diagnosis of different types of dementia, including National Institute of Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria for AD [36], revised consensus criteria from the 
DLB consortium [37] for DLB and guidelines from the Movement Disorder Society [38, 39] 
for PD dementia. Despite the availability of specific procedures for the differential diagnosis 
of AD, DLB, PD and PDD, the overlapping clinical and pathological characteristics of the 
diseases can lead to misdiagnosis. Relatively few reports have been published with a 
comparison of the features of AD, DLB and PDD in the same study [40-43].  
1.5.1 Clinical assessment of dementia 
The clinical assessment of dementia is mainly based on the medical history and evaluation of 
the cognitive ability of the patients with cognitive tests. Initial screening tests may be used 
such as the Mini-Mental State Examination (MMSE). More targeted testing may assess 
language, e.g. Boston-naming test; psychomotor speed, e. g. Trail Making test A and B; 
verbal memory, e.g. California Verbal Learning test; as well as complete neuropsychological 
batteries, e.g. the Halsted-Reitan battery. Assessment of depression is important since 
depression is a risk factor for subsequent dementia; and may be the presenting symptom of 
dementia, as well as act as a confounding factor in cognitive testing [44]. Unified Parkinson’s 
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Table 1. Characteristic features of AD, DLB and PD  
  AD DLB PD 
Neuropsychiatric symptoms 
Visual hallucinations + +++ ++ 
Delusions ++ +++ + 
Depression ++ ++ ++ 
Apathy ++ ++ + 
  
Hallucinations in late 
stages of disease 
Persistent hallucinations 
early in course of disease 
In association with 
anticholinergic 
dopaminergic drugs 
Tremor − ++ +++ 
Rigor + +++ +++ 
Bradykinesia + +++ +++ 
  
Rare, usually mild in 
late stages 
Similar severity as in PD, 
pronounced rigidity and 
bradykinesia 
First manifestation of 
disease, initially often 
asymmetric 
Fluctuation of 
cognition 
+ +++ − 
    
Prominent, severe, early 
in the course 
  
Neuropsychology 
Early impairment of 
declarative memory 
and retention 
Early disturbances in 
attention, visuo-
perceptive functions 
Impaired executive 
functions 
Neuroimaging 
Global brain atrophy ++ ++ − 
Medial temporal lobe 
atrophy 
+++ + − 
Occipital 
hypoperfusion 
  +++ + 
Impaired 
dopaminergic activity 
− +++ +++ 
Neuropathology and chemistry 
Senile plaque density +++ ++ − 
Tangle density +++ ++ − 
Subcortical LB − ++ +++ 
Cortical LB − +++ + 
Cholinergic deficit ++ +++ + 
Dopaminergic deficit − ++ +++ 
Genetics 
Overrepresentation 
APOE4 
++ ++ − 
  
+++ Indicates typical manifestation of disease, ++ indicates usually present, + indicates 
present, − indicates absent 
Mandal, P.K., et al., Neurochemical Research 
Reprinted with permission from Neurochemical research.  
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Disease Rating Scale (UPDRS) and Hoehn and Yahr Staging are commonly used 
standardized instruments to assess the severity or stage of Parkinsonism in patients. Table 1 
shows a comprehensive note of the observed neuropsychiatric, neuropathological, 
neurochemical, neuroimaging and genetic differences between AD, DLB and PD patients 
1.5.2 Pathophysiological markers in dementia 
1.5.2.1 Cholinergic system and its markers 
(i) Cholinergic versus Cholinoceptive markers 
Cholinergic system is comprised of nerve cells, which use the neurotransmitter ACh for the 
transduction of action potentials both in the central and peripheral nervous system. These 
nerve cells are defined as cholinergic if they are capable of producing and releasing ACh. In 
contrast, all other cells, including cholinergic neurons could be cholinoceptive, if they express 
ACh receptors, which are activated by the ACh molecule. The enzyme, choline 
acetyltransferase (ChAT, EC 2.3.1.6), reversibly catalyzes the synthesis of ACh from its 
precursors molecules choline -- a natural amine found in various fatty acids in the lipid  
 
 
Figure 1. The chemical reaction involved in Acetylcholine (ACh) synthesis.  
The synthesis of ACh from choline (Ch) and acetyl coenzyme A (Acetyl CoA) is catalyzed by the 
enzyme choline acetyltransferase. After its release, ACh is hydrolyzed by the cholinesterases into 
Ch. The source of Acetyl CoA is believed to be from the Citric acid cycle in mitochondria.  
 
bilayer of the cell membrane, and acetyl coenzyme A (Acetyl CoA) -- a thioester used in 
metabolic reactions that acts as an acceptor and donor of acetyl groups [45]. The ACh 
produced in the nerve cells are packed inside small vesicles with the help of VAChT, which 
are then released into the synapses during an action potential. In the synapse, ACh binds to its 
receptors, namely nicotinic (nAChRs) and muscarinic (mAChRs) ACh receptors present in 
the adjacent cells. Following the dissociation from the receptors, ACh is readily hydrolyzed 
by the cholinesterases (ChE): AChE (EC 3.1.1.7) and butyrylcholinesterase (BuChE, EC 
3.1.1.7) into choline and acetic acid (Figure 1). The choline from the ACh hydrolysis is 
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mostly recycled through active reuptake by a high affinity choline transporter into the 
cholinergic cells [46-48] (Figure 2). 
(ii) Choline acetyltransferase (ChAT) 
The involvement of ChAT in ACh synthesis has been known since 1943 [49]. However, the 
extremely low amounts and instability of this enzyme in tissues, make it difficult to analyze 
its biochemical and structural functions. Normally ChAT exists in two different forms -
soluble form and non-ionic membrane bound form in the cholinergic nerve terminals. The 
soluble ChAT contributes to 80-90% of the total enzyme activity, whereas the membrane 
bound ChAT contributes to 10-20% of the enzyme activity [50]. Different splice variants of 
ChAT such as M, R and N types have been identified from the coding gene region at the 
‘‘cholinergic gene locus’’ in rodents and humans. All splice variants produce the same ChAT 
isoform in rodents. Whereas, in humans the M-type mRNA has the ability to generate both 
large (82 kDa) and small forms (69kDa) of ChAT and R-type and N-type ChAT mRNA 
generates a small form, which corresponds to the rodent ChAT [50]. Another classification of 
ChAT refers to a common type (cChAT) in the central nervous system (CNS) and a 
peripheral type (pChAT), the latter which is preferentially expressed by the peripheral 
neurons and is expected to have a Mw of 50 kDa [51]. Studies also report the presence of 
small 27kDa ChAT protein produced by another mRNA splice variant. This smaller variant 
appears to lack the catalytic activity, but it might have a regulatory role on the activity of full-
length ChAT [52]. The different genetic variants of ChAT gene is also found to be associated 
with the cognitive decline in AD patients [53]. 
Several studies from the past have shown the existence of the ACh synthesizing enzyme, 
ChAT in the intracellular compartments.  But in order to modulate immune functions, ACh 
must diffuse to a considerable distance from the cholinergic nerve terminals, resisting the 
action of two extremely efficient ACh-degrading enzymes, AChE and BuChE, which are 
abundant in the extracellular fluids such as plasma and CSF. In addition, the immuno-
suppressive activity requires that ACh to be present at certain extrasynaptic levels to exert its 
putative role on immune cells by activating a7-nAChR ion-channels. Hence, a link is missing 
for the distant action of ACh in the cholinergic anti-inflammatory pathway. Considering the 
cholinergic hypothesis in dementia, the role of ChAT in AD, DLB, PD and PDD patients in 
maintaining the ACh levels in the brain and the interstitial fluids needs more clarification.  
 
 
 20 
 (iii) Acetylcholinesterase (AChE) 
AChE encoded by a gene on chromosome 7 is the most predominant form of cholinesterase 
in the brain. It helps in terminating the synaptic neurotransmission by acting on the ACh 
molecule, which is hydrolyzed by them into choline and acetic acid. It is expressed in both 
cholinergic and non-cholinergic neurons in the central and peripheral nervous system. 
Additionally AChE is expressed in lower proportions by the cells and tissues in the brain 
and elsewhere such as in the meninges and glial cells [54]. Studies also show its presence in 
the red blood cell membranes [55]. Three different splice variants of AChE exist, namely 
the synaptic variant (AChE-S), the read-through variant (AChE-R) and the erythrocytic 
variant (AChE-E). The synaptic form constitutes the major species in the brain and mostly 
exists as a globular tetrameric form (G4). The AChE-R mostly exists as a monomeric (G1) 
form in the brain and the AChE-E exists as a glycophosphoinositol (GPI) anchored dimers 
(G2) [54]. 
The membrane bound AChE plays an important role in maintaining the ACh levels in the 
cholinergic synapses. High AChE activity in brain is considered as a typical characteristic 
of dementia, which causes an imbalance in ACh levels and, thereby, leads to cognitive 
symptoms in patients. Apart from the major role as ACh hydrolyzing enzyme, AChE also 
plays an important role in neurogenesis, cell adhesion, synaptogenesis, activation of 
dopamine neurons, promoting amyloid fiber assembly, hematopoiesis and thrombopoiesis 
[48]. The splice variants AChE-S and AChE-R are found to be associated with dementia 
and previous studies from our group have shown that AChE R/S ratio is reduced in 
untreated AD patients, and it’s increase after treatment with cholinesterase inhibitors 
(ChEIs) constitutes a positive sign [56].  
(iv) Butyrylcholinesterase (BuChE) 
BuChE also known as pseudo cholinesterase is a serine hydrolase, and is responsible for the 
hydrolysis of ACh in the extracellular fluids. It acts as a co-regulator of cholinergic system 
along with AChE. In human brain the glial cells are the major source of this enzyme. 
However, it is also expressed in the neurons and endothelial cells in both central and 
peripheral nervous system. The BuChE also exists in three molecular forms such as G1, G2 
and G4, which are all symmetrical, hydrophilic, and globular. The G1 form is predominant in 
the developing brain, whereas the G4 form is predominant in the mature brain [57].  
The butyrylcholinesterase gene (BCHE) is located in the long q-arm of chromosome 3 and 
over 40 mutations have been identified in this gene. The BCHE-K variant is the most 
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common polymorphism of BCHE, which is resulted due to the substitution of an alanine 
residue at codon 539 to threonine (A539T). Other mutations of BCHE gene include the 
atypical, J, H, and silent variants. The distribution and activity of BuChE in CSF, brain and 
serum varies depending on the type of genetic variant present in an individual [57].  
Recent studies have indicated a high level of BuChE protein and activity in the brain and CSF 
of dementia patients [57]. Evidences shows large amount of BuChE deposits in amyloid 
plaques and neurofibrillary tangles in dementia patients suggesting an important role of 
BuChE in dementia especially in AD [57, 58].  
(v) Cholinergic hypothesis in AD 
During senescence and dementia, degeneration of the cholinergic neurons occur in the 
cerebral cortex and hippocampus regions of the brain, which are responsible for cognitive 
functioning. This leads to a decrease in ACh mediated neurotransmission and ACh levels in 
the brain and periphery thereby causing cognitive deficit [59, 60].  
 
 
Figure 2. Cycle of acetylcholine. Acetylcholine is produced in the presynaptic neuron by the 
enzyme choline acetyltransferase from acetyl-coenzyme A and choline, and later released in the 
synaptic cleft where it binds to the acetylcholine receptor on the postsynaptic membrane, initiating 
an action potential and/or triggering an intracellular response. The enzyme acetylcholinesterase 
hydrolyses acetylcholine into acetate and choline in order to terminate synaptic transmission. 
Choline is transported into the presynaptic neuron by the choline carrier and serves as a substrate 
for the described production of acetylcholine. By inhibiting the enzyme acetylcholinesterase, the 
AChEIs prevent the breakdown of acetylcholine into acetate and choline, prolonging its duration of 
action. 
Jeger, R.V.,European heart journal 
Reprinted with permission from European heart journal.  
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ACh through the cholinergic anti-inflammatory pathway, helps the nervous system to exert 
immuno-modulatory effects on the systemic immunity [61, 62]. This is coined, the 
cholinergic anti-inflammatory reflex or pathway (CAP). In this context, ACh putatively acts 
as a suppressor of inflammatory responses by lymphocytes by binding to the α7nAChRs 
present in these cells [63]. 
1.5.2.2 Apolipoprotein E (ApoE) 
Human ApoE protein is a 299-amino acid glycoprotein with a molecular weight of 34kDa, 
which is expressed by several cell types in the central nervous system. ApoE is one of the 
major classes of lipoproteins in brain and is primarily expressed by astrocytes and microglia 
[64]. The highest production of ApoE in periphery occurs in the liver. ApoE plays a major 
role in mediating cholesterol metabolism and lipid transportation [64]. 
In human, APOE gene is located in the chromosome 19. There are three major alleles of 
APOE namely ε2, ε3 and ε4 expressing ApoE2, ApoE3 and ApoE4 isoproteins, respectively. 
The three isoforms of ApoE differ from each other at the amino acid residues 112-158 which 
contains either cysteine or arginine. ApoE3, the most common isoform contains Cys112, 
Arg158; APOE4 the next common isoform contains Arg112, Arg158 and APOE2 the least 
common isoform has Cys112 and Cys158. The single amino acid difference in these protein 
isoforms alters its ability to bind to receptors, ligands and other associated proteins such as 
Aβ (Figure 3[65]).  
 
 
 
Figure 3. Structural difference between ApoE3 and ApoE4. 
Zhong and Weisgraber,Trends in molecular science 
Reprinted with permission from Elseiver.  
APOE3 is the most common type of allele and is present in more than half of the general 
population [66]. APOE4 genotype is considered as the major risk factor for AD, whereas 
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APOE2 genotype has been found to be a protective factor [67].  APOE4 may also act as a 
risk factor in other types of dementia such as DLB [68].  
The level of ApoE in CSF varies with the specific type of APOE genotype. Previous studies 
from our group show that APOE4 is associated with high CSF ApoE levels in AD patients 
[69]. APOE4 may also trigger inflammatory cascades in the brain, which could have an 
impact on the pathogenesis in dementia patients [70].  
ApoE binds to several receptors belonging to the low-density lipoprotein receptor (LDLR) 
family in an isoform dependent manner. ApoE and its receptors may play a major role in Aβ 
aggregation and clearance, which also varies with the different isoform of the ApoE protein. 
[71]. Recently, it has been shown that ApoE may also interact with Aβ and prevents its fibril 
formation in a concentration and isoform dependent manner [72]. Apart from this, ApoE and 
its receptors also seem to play a vital role in Tau phosphorylation, amyloid precursor protein 
(APP) processing, synaptic plasticity, brain atrophy, neuronal cell survival and integrity [68, 
71]. 
1.5.2.3 Amyloid precursor protein (APP)  
APP is an integral transmembrane protein and the APP gene is located in the chromosome 21 
in humans. The cleavage of APP occurs in two ways, namely, amyloidogenic and non-
amyloidogenic pathway. In the non-amyloidogenic pathway, APP is cleaved by the enzymes, 
ϒ-secretase and α-secretase. The latter cleaves APP at an epitope within the Aβ sequence in 
APP protein, excluding the production of Aβ peptides and producing a small p3 peptide, a 
soluble APPα (sAPPα), and APP intracellular domain (AICD) fragments. Whereas in the 
amyloidogenic pathway, APP is cleaved at by ϒ-secretase and β-secretase producing the Aβ 
peptide (an Aβ 40, 42 or 43), sAPPβ and an AICD fragment. Hence by definition, high levels 
of sAPPβ in the brain could indicate the prevalence of amyloidogenic pathway and hence 
more Aβ production which could aggregate and accumulate as Aβ plaques. However, the 
differences between the levels of sAPPα and sAPPβ in the CSF remains unclear, especially in 
sporadic AD [73]. Thereby, the amyloidogenic and non-amyloidogenic terminology might be 
misleading, in particular, since Aβ production is apparently a native biological process, since 
it occurs in all human subjects regardless of age or disease. Whilst “amyloidogenic” ascribes 
a general protein aggregation process that may occur for diverse proteins, such as prions, α-
synuclein, huntingtin, serum amyloid A, etc. Thus usage of the neutral terms, α-secretase and 
β-secretase cleavage pathways, are best justified. 
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Nonetheless, sAPPα is associated with several protective functions in the brain such as 
promoting neurite outgrowth, synaptogenesis and cell adhesion, although the exact 
mechanisms behind its functions is not fully understood. sAPPβ lacks the neuroprotective 
effects when compared to sAPPα, but seems to be critically involved in the pruning of 
synapses during the development of both the central and peripheral neurons [73].   
1.5.2.4 Amyloid β and Tau 
APP, undergoing amyloidogenic (β-secretase cleavage) pathway produces Aβ fragments of 
varied length, such as Aβ 38, Aβ 40 and Aβ 42. Such Aβ deposition in the brain is considered 
as one of the hallmarks in AD pathogenesis. If present in excess (and/or under certain 
conditions), these peptides form fibrils and accumulate as plaques in the brain of patients with 
AD and other dementia such as DLB and PDD. Aβ 42, which is generally believed to be the 
most neurotoxic Aβ peptide, is known to be hydrophobic, and prone to aggregate much faster 
than Aβ 40 and Aβ 38. The typical AD pathology includes the presence of high Aβ 
aggregates in the brain and low Aβ42 in CSF. There are different molecular forms of Aβ, 
such as monomers, dimers, tetramers, oligomers, fibrils, plaques etc. However, which 
molecular form of Aβ is most toxic and acts as a key cause for AD or other dementia is 
unclear. There are no general correlations between cognition and/or clinical severity of the 
disease and the Aβ levels in CSF or the brain (PET-tracer data). For instance, MCI patients 
exhibit similar levels of Aβ deposits as AD patients, and ~30% of control subjects are Aβ-
PET positive. Aβ might nonetheless be associated with AChE, BuChE, ApoE and 
inflammation in the brain and CSF thereby increasing the risk of dementia [74-76].  
Neurofibrillary tangles are intracellular deposits of hyper-phosphorylated Tau protein in the 
brain, constituting another major hallmark of AD and the related dementias. Tau is a 
microtubule-associated protein, abundantly present in the central and peripheral nervous 
system. It helps in microtubule assembly and its stabilization in the brain. During dementia, 
hyper-phosphorylation of Tau alters the microtubule stability resulting in loss of synapses, 
tangle formation and neuronal death. Tau protein levels in CSF and brain are also associated 
with poor cognition in dementia patients [77].  
1.5.3 Neuroimaging markers in dementia  
Neuroimaging has become a very important diagnostic tool in dementia to investigate the 
structural, functional and pathological changes in the brain. Some of the commonly used 
neuroimaging biomarkers for dementia diagnosis are listed below. 
  25 
1.5.3.1 Structural imaging 
Computed tomography (CT) and magnetic resonance imaging (MRI) are commonly used for 
determining the structural changes in the whole brain and specific regions of the brain. The 
different modes in MRI give detailed information regarding the volumetric changes in the 
brain such as atrophy, micro-bleeds and grey and white matter changes. CT and MRI are used 
for primary clinical diagnosis of dementia due to cheaper cost and ease of use [78]. These 
techniques also helps to rule out the structural lesions in dementia [79].  
1.5.3.2 Functional imaging 
The alterations in the neuronal activity in the brain while performing cognitive tasks are 
characterized by altered blood flow in the brain, which is measured using functional MRI 
(fMRI). Resting state fMRI helps in measuring the functional changes in the resting-state 
networks of the brain. It also helps in measuring the functional changes in the brain of 
patients who are too impaired to perform any cognitive tasks. Thus, fMRI provides 
information regarding the functional changes in the brain due to neurodegeneration [78]. 
1.5.3.3 Glucose metabolism in brain 
Positron emission tomography (PET) involves the injection of a radiolabelled compound into 
the body to bind with the target of interest. 18F-fluorodeoxyglucose (18F-FDG)-PET is used 
to measure the glucose metabolism in the brain. Dementia patients exhibit low glucose 
metabolism in the brain, which is associated with increased neurodegeneration [78].   
1.5.3.4 Brain perfusion 
Single-photon emission computed tomography (SPECT) involves the use of a radiolabelled 
ligand to study cerebral brain perfusion, which gives a measure of the regional blood flow in 
the brain and is used as an indicator of severity in dementia [78, 79]. Brain perfusion 
measured using arterial spin labeling (ASL) provides quantitative imaging of the cerebral 
blood flow using MRI equipment. This could help in the early characterization of AD [80] 
1.5.3.5 Amyloid-beta deposition in the brain 
The Aβ deposition in the brain is commonly measured with the help of 11C-Pittsburgh 
compound B (PIB)-PET. The presence of high Aβ in the brain constitutes for the major 
pathological changes in AD and DLB patients and this pattern of Aβ deposition vary between 
different brain regions in different type of dementia. The 11C-PIB when injected into the body 
binds putatively to fibrillar forms of Aβ deposits in the brain and thus this method of brain 
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imaging along with other imaging techniques such as CT, MRI and 18F-FDG-PET might help 
in the differential diagnosis of dementias such as AD, DLB, PD and PDD [78, 81]. Apart 
from 11C-PIB, there are also other PET tracers available for Aβ imaging, such as 18 F-
flutemetamol, 18 F-florbetapir and 18 F-florbetaben. However, the diagnosis with PET 
imaging due to its higher costs, cannot be afforded for all dementia patients. Figure 4 shows 
the amyloid imaging in the brain of AD, DLB, PD, PDD patients and aged healthy control 
[82].  
 
Figure 4. Amyloid imaging (PIB-PET) in the brain of normal aging individual, AD, PD, PDD 
and DLB patients. Images from a 75-year-old normal control (NC) (upper left), a 79-year-old patient 
with Alzheimer disease (AD) (Mini-Mental State Examination (MMSE) score 25; upper right), a 65- 
year-old patient with Parkinson disease (PD) (MMSE score 27; lower left), a 69-year-old patient with 
PD dementia (PDD) (MMSE score 25; lower middle), and a 71-year-old patient with dementia with 
Lewy bodies (DLB) (MMSE score 8; lower right) are displayed. Note that Pittsburgh Compound B 
(PiB) retention is qualitatively increased in AD, PDD, and DLB compared with NC and PD. Note also 
the variation in the regional distribution of amyloid across the AD, PDD, and DLB images. 
DVR=distribution volume ratio.  
Gomperts, S., et al., Neurology 
Reprinted with permission from Neurology.  
 
 
1.5.3.6 Dopamine load in brain 
The dopamine depletion in the brain results in movement disorders associated with the 
Parkinsonism observed in DLB, PD and PDD patients. The dopamine load in the brain can be 
visualized by measuring the Dopamine transporter (DAT), which is located presynaptically 
on the dopamine releasing terminals using DaTscan-SPECT. The vesicular monoamine 
transporter (VMAT) and amino acid decarboxylase (AADC) present in the dopamine 
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releasing neuronal terminals can be measured using 11C- Dihydrotetrabenzine (DTBZ) and 
18F-dopa respectively. These three scans greatly help in studying the dopamine deficit in the 
brain and thereby also help in differentiating PD, PDD and DLB from healthy subjects and 
other kinds of dementias with high accuracy [81, 83].  
1.5.3.7 Other neuroimaging markers 
Recently there have been studies reporting the development of a radioactive PET tracer for 
quantifying the Tau protein in the brain, which is also a hallmark of AD and 
neurodegeneration in dementia [84]. Also the astroglial activity in brain, which is associated 
with neuroinflammation and neurodegeneration in dementia is studied in vivo using 
autoradiography techniques [85]. PET imaging of cholinergic markers such as 
acetylcholinesterase (AChE) and SPECT imaging for α4β2nAChRs and vesicular 
acetylcholine transporter (VAChT) have also been developed for the better understanding 
of cholinergic system in dementia patients [86].  
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2 AIMS 
2.1 GENERAL AIMS 
 To understand the inter-relationship between ApoE and the cholinergic enzymes 
(AChE, BuChE and ChAT) along with APOE4 and BCHE-K genotype in dementia 
patients, especially in AD and DLB.  
 To study the association of ApoE and cholinergic enzymes with cognitive decline and 
other AD related dementia markers such as Aβ, Tau and APP in AD and DLB 
patients.  
 To study the underlying mechanism behind the interaction of ApoE, Aβ and BuChE 
in dementia. 
2.2 SPECIFIC AIMS 
2.2.1 Study 1 
 To investigate the relationship between the levels of ApoE protein and 
neurodegenerative markers in CSF of patients with DLB, PDD, PD without dementia 
(PDND) and healthy controls (HC). 
2.2.2 Study 2 
 To explore, whether ChAT exist in extracellular fluids, it sources, if it is functionally 
intact, if it is capable of  maintaining a certain extrasynaptic ACh level and to study 
the interrelationship of soluble ChAT with markers of inflammation and immune 
system. 
2.2.3 Study 3 
 To study the distribution of BCHE-K genotype and its association with APOE4 
genotype and cognitive decline in AD and DLB patients. 
2.2.4 Study 4 
 To study ApoE and cholinergic markers in CSF of AD and DLB patients, along with 
their genotypes (APOE4 and BCHE-K) and their association with other CSF markers 
representing AD pathology such as sAPP, Aβ and Tau.  
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3 MATERIALS AND METHODS 
3.1 PATIENT COHORTS  
3.1.1 Study 1 
The patient cohorts used in this study consisted of five healthy controls (HC) and 28 patients 
with Lewy body disorders (nine with DLB, nine with PDD and 10 with PDND) who fulfilled 
the clinical criteria for PD and DLB [37, 87]. The patients were recruited by experienced 
neurologists from the Neurodegenerative Department, University of Tuebingen (Tuebingen, 
Germany), using a standardized clinical examination procedure, which was expected to have 
an accuracy of more than 90% for the correct diagnosis [88]. In addition, all the patients 
underwent an extensive neuropsychological test battery. The diagnosis of PDD was based on 
the clinical diagnostic criteria, DSM-IV [89] indicating cognitive impairment in at least two 
domains that included memory dysfunction and the clinically rated impact on activities of 
daily living functioning. The clinical ratings were based on the reports from either the 
patients or caregivers regarding the daily living dysfunction caused primarily due to cognitive 
worsening. The differentiation of DLB from PDD was done with the 1-year rule.  In other 
words, PDD was diagnosed, if dementia occurred later than 1 year after the first occurrence 
of motor symptoms and DLB was diagnosed if dementia occurred no later than 1 year after 
the first occurrence of motor symptoms or even preceded motor symptoms [37]. The 
participants also underwent imaging with MRI shortly before the study to exclude atrophy 
and severe deep white matter lesions, which are typical signs for vascular pathology. All 
participants underwent the assessments reported here within the time frame of 1 month [90]. 
The demographic details of the patients included in this study are reported in Table 2. 
3.1.2 Study 2  
We prepared nine pooled samples of plasma and CSF from patients with defined APOE and 
BCHE genotypes by pooling equal volumes of at least three samples with identical 
genotypes, from 179 patients who had a clinical diagnosis of mild to moderate AD recruited 
form Geriatric Clinics in Karolinska University Hospital, Huddinge, Sweden or from Pitea 
River Valley Hospital, Sweden. The selection and diagnosis of patients was made using an 
exclusionary criterion- absence of diagnosis of any other dementia, in accordance with the 
NINCDS-ADRDA [36]. All the samples were those collected prior to treatment with ChEIs. 
More details regarding the study population is reported in [58].  
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Brain tissues were obtained from five AD patients (mean age 78±5 years, postmortem delay 
26±2 hours, nonsmoking) and five non-AD controls (mean age 82±2years, postmortem delay 
21±4 hours, nonsmoking) provided by Netherland Brain Bank.  
The study also included CSF samples from 10 patients who were diagnosed with multiple 
sclerosis (MS) and 11 patients with other non-inflammatory neurological conditions (OND). 
These patients were those who were attending the Neurology clinic, Karolinska University 
Hospital, Solna. The clinical examinations were performed by experienced specialists in 
neurology and the MS patients were diagnosed based on the McDonald criteria [91]. The MS 
patients were also evaluated with the Expanded Disability Status Scale (EDSS) at the time of 
sampling by a certified rater [92].  
The OND group of patients did not have any inflammatory neurological/psychiatric 
conditions when assessed with MRI scan and did not have any signs of inflammatory activity 
in CSF. No evidence of concomitant diseases such as infections was found in these patients. 
Corticosteroids had not been given within three months of sampling. 
Table 2. Demographic details of patient cohorts in Study 1 
 
 
Values are displayed as median (range). #p value between DLB, and patients with PDD and PDND. 
*p value between groups with dementia (PDD and DLB) and groups without (PDND and HC). 
 
Diagnosis group HC DLB PDD PDND p-value 
N 5 9 10 10  
Age at PIB-PET 
(years)  
66.0 (56-80) 69.0 (62-76) 69.5 (62-80) 66 (55-83)  
Gender (F/M) 3/2 2/7 6/4 2/8  
APOE4 (+/-) 0/5 6/3 3/7 1/8 #p<0.020 
Hoehn and Yahr stage - 2 (2-3) 2 (2-3) 2 (1-4)  
Age at onset of 
Parkinsonism (years) 
- 66 (59-73) 59.5 (55-70) 56.0 (49-75) #p<0.030 
Duration of 
Parkinsonism (months) 
- 36 (24-60) 108 (60-168) 96 (24-204) #p<0.006 
Age at onset of 
Dementia (years) 
-  67 (59-73) 67 (61-78) -  
Duration of Dementia 
(months) 
- 36 (24-48) 24 (15-36) - #p<0.025 
MMSE  29.0 (27-30) 19 (18-27) 23.5 (19-30) 28.5 (26-30) *p<0.0001 
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3.1.3 Study 3 
The overall study cohort consisted of 368 ethnic Norwegians who were recruited as a part of 
two large ongoing studies in Norway namely DemVest and TrønderBrain study. Of these 
individuals, there were 108 were AD patients, 174 were DLB patients and 86 were Controls. 
All AD and a portion the of DLB patients belonged to the DemVest study, and had been 
recruited from the dementia clinics in western Norway [93]. The additional DLB patients and 
controls belonged to TrønderBrain study and were recruited through hospitals, outpatient 
clinics, nursing homes, or from local care authorities in central and southwestern parts of 
Norway. The control subjects included caregivers not genetically related to the patients, and 
other elderly volunteers recruited from societies for retired people in the same area, all 
without first-degree relatives with dementia. All the controls, were healthy for their age, 
and when tested, did not have cognitive deficits [67, 94].  The diagnosing of AD and DLB 
patients was performed as described in [93, 94].  The gross cognitive screening in these 
patients was performed with MMSE and the DemVest patients had an annual cognitive 
assessment with MMSE for up to five years. Table 3 provides information regarding the 
baseline clinical and demographic characteristics of the study cohorts.  
Table 3. Baseline clinical and demographic characteristics of subjects in Study 3 
 
&&&p<0.001 are significant differences between AD and DLB; **p<0.01 are significant differences 
between controls and AD; #p<0.05 is significant difference between Controls and DLB; $$$p<0.001; 
$$p<0.01is significant difference between Demvest and Tronderbrain DLB. Values are given as the 
mean ± standard deviation. 
 
3.1.4 Study 4  
This study includes a subgroup of about 33 AD patients, 10 DLB patients and 13 healthy 
controls from the DemVest study, which was described in Study 3. The diagnostic 
procedures of these patients were similar to those described in Study 3. The healthy controls 
were recruited from the patients visiting the clinic for elective orthopedic surgery or 
DIAGNOSIS DLB AD CONTROLS 
CENTRES 
DEMVEST 
(N=75) 
TRØNDERBRAI
N 
(N=99) 
TOTAL 
(N=174) 
DEMVEST 
(N=108) 
TRØNDERBRAIN 
(N=86) 
FEMALES (%) 47 43 44&&& 71 49 ** 
AGE (YEARS) 75.4±7.4 76.9±7.8 76.3±7.6 74.6±7.8 73.9±5.9# 
DISEASE 
DURATION 
(YEARS) 
3.3±2.3$$ 4.6±3.1 4.0±2.9&&& 2.5±1.8 NA 
MMSE 23.6±3.3$$$ 19.3±7.0 21.3±6.0&&& 24.0±2.3 NA 
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neurological outpatient assessment, who did not have any known neurological diseases and 
were confirmed cognitively normal after an interview and cognitive screening with MMSE 
[95, 96]. Table 4 gives detailed information regarding the study cohorts in Study 4.  
Table 4. Characteristics of the study cohorts in Study 4 
 
The values are given as median (range) or number (%). ***p<0.001 and **p<0.01 represents the 
significant difference between controls and demented groups (AD and DLB). 
 
 
3.2 ETHICAL CONSIDERATIONS 
Written informed consent was obtained from the patients or their proxies, and from the 
control individuals involved in all four studies. The studies were conducted according to the 
Declaration of Helsinki and the subsequent revisions.   
 Study 1 was approved by the ethical committee from the University clinic at 
Tübingen, Germany (Ethik-Kommission an der Medizinischen Fakultät der Eberhard-
Karls-Universität und am Universitätsklinikum Tübingen). 
 Study 2 was approved by either the regional ethical review board in Stockholm or the 
research ethics committee of the south location, Huddinge University Hospital, 
Sweden.  
 Study 3 and 4 was approved by the regional ethical committee for health and medical 
research ethics in western Norway (for the DemVest Study) and by the regional 
ethical committee for health and medical research ethics in mid Norway (for the 
Trønderbrain study).  
The obtained ethical permissions also included the permit to transport the samples abroad. 
3.3 SAMPLE PREPARATIONS 
All the samples used in the studies were collected/prepared, transported, aliquoted, diluted 
and stored at -80°C prior to the experimental procedure. 
DIAGNOSIS 
AD 
(n=33) 
DLB 
(n=10) 
CONTROL 
(n=13) 
Female (%) 70 40 67 
Age  74(50-89) 73(55-84) 78(66-84) 
BL-MMSE 24(20-29)*** 26(22-28)$$ 28(26-30) 
BCHE-K Carriers (%) 48 30 NA 
APOE4 Carriers (%) 73 70 NA 
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3.3.1 CSF collection and storage 
CSF was taken from all the subjects by lumbar puncture using polypropylene tubes. Routine 
CSF diagnostics (cell count, albumin, immunoglobulin G level, immunoglobulin G index, 
and cytology) were performed. Further details regarding the CSF collection in Study 1 is 
reported in [97], Study 2 in [58] and Study 4 in [96]. The CSF samples were centrifuged 
within 1 hour after collection and stored at -70°C until analysis. 
The CSF from the study cohorts collected from the respective hospitals were transported to 
the laboratory at Karolinska Institutet, Stockholm, Sweden as per the standard transportation 
procedures in dry ice. The samples were aliquoted, diluted as per the desired dilutions for 
specific experiments and stored at -80°C. Later the diluted samples were taken out and 
thawed while performing the experiments. 
3.3.2 Preparation of brain homogenates  
In study 2, the cortical brain homogenates (BH) from parietal cortex of five AD patients and 
five non-AD controls were prepared as described previously in [56]. The pooled BH samples 
were prepared from each group and stored at -80°C for the experiments. 
3.3.3 DNA extraction 
For study 3, the blood samples were collected and handled according to standardized 
procedures, aliquoted, frozen, transported and stored at –80°C at Karolinska Institutet, 
Stockholm, Sweden. DNA was extracted from approximately 3mL of whole blood using the 
Gentra Puregene blood kit (cat no. 158389) from Qiagen according to the manufacturer’s 
instructions and was stored at -80°C.  
3.4 PROTEIN AND ACTIVITY MEASUREMENTS 
Different kinds of Enzyme linked immunosorbent assay (ELISA) such as sandwich ELISA, 
direct ELISA and multiplex-ELISA was performed to quantitatively measure the 
concentrations of different proteins. The activity of enzymes was measured using a functional 
assay integrated with a sandwich ELISA or ELISA-like assay setup. All the ELISAs were 
performed either in a 96-well or 384-well microtiter plates (Nunc Maxisorb, Cat no 236366, 
Denmark) and the reaction was monitored at specified wavelength using an Infinite H M1000 
Tecan microplate reader.  
The ELISA methods used for the measurement of AChE, BuChE, ChAT and ApoE were all 
designed, developed and validated in our lab by the members of Darreh-Shori’s group. 
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(i) ApoE protein levels 
For ApoE measurements, all the CSF samples were diluted 50X in advance with TBS- T0.2% 
(10mM Tris–HCl, pH 7.4; 0.2% Tween-20; all from Sigma), and used in a sandwich ELISA 
protocol reported previously [69] 
(ii) AChE and BuChE protein levels and activity 
For AChE and BuChE measurements, the CSF samples were diluted 5X with dilution buffer 
[TBS (10mMTris–HCl); 0.1% BSA  (Bovine serum albumin); 1mM EDTA 
(Ethylenediaminetetraacetic acid) and 0.05%Triton X-100; All reagents were from Sigma 
Aldrich]. The protein level of AChE-R and AChE-S variant was measured separately using 
specific antibodies by ELISA-like assays [98]. The total and the functional BuChE protein 
concentrations were measured using a sandwich ELISA and an ELISA-like assay, 
respectively, as described in [58]. The AChE and BuChE activities were measured using a 
modification of Ellman’s calorimetric method, using acetylthiocholine iodide (ATC) and 
butyrylthiocholine iodide (BTC) as substrates, respectively. We used ethopropazine, a 
BuChE inhibitor while measuring the AChE activity and BW284C51, a selective AChE 
inhibitor while measuring the BuChE activity [58, 98].  
(iii) ChAT protein levels and activity 
In Study 2, we developed a new unique, simple, non-radioactive and sensitive technique for 
determination of ChAT activity and protein concentration. Both ChAT protein and activity 
measurements were done in a single assay in a 384 well microtiter plate (Nunc Maxisorb, 
Denmark). ChAT protein and activity in CSF, BH, plasma and cell medium were measured 
using the new method. 
The ChAT activity measurement is based on the ChAT chemiluminescence assay by [99] and 
we have done several modifications to improve the handling of samples, the control blanks 
and the detection system. We used native and denatured samples in our assay, where the 
denatured samples served as a control for both ChAT activity and endogenous concentration 
of choline in the samples.  
The ChAT protein concentration was measured using sandwich ELISA. We tested the 
sensitivity and specificity of our ChAT sandwich ELISA using different pairs of antibodies 
and found that the combination of the anti-ChAT mouse monoclonal antibody (MAB 3447, 
R&D System, UK) as the capturing antibody and anti-ChAT rabbit polyclonal antibody (PAB 
14536, Abnova Corp. Taiwan) had less unspecific binding with less variations and noise to 
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signal ratio compared to other antibodies. We used a recombinant human ChAT protein 
(R&D systems) as standards for this assay. 
Since the main objective of the Study 2 is to show the presence of extracellular ChAT, we 
used reagents recognizing both the N and R type splice variants and the common and 
peripheral ChAT isoforms, instead of reagents specific to a particular isoforms of ChAT.  
A comprehensive description of this assay is described in the published study paper. 
(iv) sAPPα and sAPPβ levels 
The sAPPα and sAPPβ measurements in Study 1 (with 50x diluted CSF) and Study 4 (4X 
diluted CSF) were performed using the duplex ELISA kits developed by Meso Scale 
Discovery, Rockville, MD, USA.  
(v) T-Tau and P-Tau levels 
The T-Tau and P-Tau measurements in Study 1 was performed using undiluted CSF in a 
duplex ELISA kit for total tau/phosphorylated tau 231 from Meso Scale Discovery, 
Rockville, MD, USA (96-well MULTI-SPOTAD assay: phosphorylated (Thr 231)/total tau 
with purified neuronal tau calibrators). The T-Tau and P-Tau 181 measurements in Study 4 
was performed using commercial sandwich ELISAs: INNOTEST hTAU-Ag and INNOTEST 
PHOSPHO-TAU (181P) (Innogenetics, Ghent, Belgium) respectively.  
(vi) Aβ38, Aβ40, and Aβ42 levels 
In Study 1 and 4, the Aβ38, Aβ40, and Aβ42 levels in the CSF samples were determined 
using a triplex ELISA kit from Meso Scale Discovery. 
3.5 SNP GENOTYPING 
The APOE4 genotyping for Study 3 and 4 was performed as described in [67]. The BCHE-K 
(rs1803274) genotyping in Study 3 and 4 was performed with purified DNA using the 
TaqMan SNP genotyping assay kit (cat no. 4351379, Applied Biosystems), and was 
confirmed in whole blood using the TaqMan Sample-to-SNP assay kit (cat no. 4403087, 
Applied Biosystems), according to the manufacturer’s instructions, using a StepOne Plus 
thermal cycler (Applied Biosystems) as described previously [58].  
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3.6 DOT BLOT AND WESTERN BLOT ANALYSES  
The presence of ChAT in CSF, plasma and BH was first tested by a simple dot-blot technique 
using anti-ChAT antibodies MAB 3447 and PAB 14536 in Study 2. This was then confirmed 
using Western-blot, which is more specific than dot-blot analysis, and also helped in 
identifying the different possible molecular forms of ChAT. 
3.7 SUCROSE-DENSITY GRADIENT ULTRACENTRIFUGATION AND 
SEDIMENTATION ANALYSIS  
Further evidence and insights about different molecular forms of ChAT were assessed by 
sedimentation analysis. Briefly, protein content of nine different pooled CSF samples were 
separated by sucrose- gradient sedimentation technique and ultracentrifugation at 1650006g 
in a continuous sucrose gradient (5–20% w/v) for 18 hours at 4°C in a Beckman rotor (SW 41 
Ti) as described previously [56]. The sucrose gradients (10 mL/tube) were prepared in TBS 
(Tris-HCl, 10 mM, pH 7.4, containing 150 mM NaCl and 50 mM MgCl2) and the pooled 
CSF (0.5 mL) or BH (0.3 mL) samples were applied on the top of the gradients. 
Approximately 50 fractions were collected from the bottom of each tube. Concentration of 
ChAT protein in the collected fractions was then determined by our sandwich ELISA. 
Enzymes of known sedimentation coefficient, bovine liver catalase (11.4S ≈ 250 kDa) and 
calf intestinal alkaline phosphatase (6.1S ≈ 140 kDa), were used in the gradients to estimate 
the sedimentation coefficient and Mw of different molecular forms of ChAT, using the 
following equations. 
Sedimentation coefficient of protein of interest, (ChAT in this case)(in Svedberg 
units, S), Sp = [(Nt-Np)/(Nt-Nr)] * Sr, 
Where,  
Nt = Number of total fractions collected from the gradient. 
Np = Number of the fraction containing the protein of interest  
Nr = Number of the fraction containing the reference protein (Catalase or alkaline 
phosphatase) 
Sr = Sedimentation coefficient of the reference protein (Sedimentation coefficient of 
catalase is 11.4S and alkaline phosphatase is 6.1S). 
 
The molecular weight of protein of interest, Mwp = (Mwr*Sp2)/ Sr2 
Where, 
Mwr = Molecular weight of the reference protein. 
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3.8 IMMUNOFLUORESCENCE AND CONFOCAL MICROSCOPY 
In Study 2, the spleen cells (106 cells/mL) from C57BL/6 mice were stimulated with 
lipopolysaccharides (LPS, 25 mg/mL) or with anti-CD3 (clone 2C11 at 5 mg/mL). The cell 
cultures were run in parallel in duplicates in RPMI1640 (HyClone Cat no SH3009601), 
supplemented with 10% fetal calf serum, 2 mM L- glutamine, 50 U/ml penicillin, 50 g/ml 
streptomycin, 10 mM HEPES, 1 mM sodium pyruvate and 50 mM 2-mercaptoethanol.  
The cells and medium were collected after 24 and 48 hours for analysis. The cells were 
washed 3 times with PBS, and mounted on adhesion slides (ER-202W-AD-CE24, Thermo 
Scientific). The cells were fixed and prepared for the subsequent confocal microscopy as 
described in [100] with minor modification. The cells were permeabilized with 0.2% saponin, 
instead of Triton-X100, for 15 min each. A rabbit polyclonal anti-ChAT antibody (AB143, 
Millipore, 1:100) was used for the immunocytochemistry of ChAT in the mice lymphocytes. 
3.9 HUMAN ASTROCYTE CULTURES 
For Study 2, primary human astrocytes were obtained from ScienCell Research Laboratories 
(Cat no 1800) and were cultured in astrocyte medium (ScienCell Cat no 1801) in poly-L-
lysine-coated T-175 flasks, and handled according to manufacturer’s protocols. Confluent 
cells were then detached, and seeded in a 48-well plate (3x105 cells/well), and left in medium 
overnight to recover. Following this, the cells were stimulated with ACh or tumor necrosis 
factor-α (TNF-α) alone, ACh+TNF-α or left unstimulated as control. ACh concentration 
varied between 1 mM to 10 mM and TNF-a concentration was kept constant at 20 ng/ml. The 
astrocytes were stimulated for 24 hours, after which the cells were lysed for RNA extraction 
and subsequent reverse transcriptase-PCR (RT-PCR) expressional analysis. 
3.10 RNA PREPARATION AND RT-PCR 
In Study 2, messenger ribonucleic acid (mRNA) was extracted from the astrocytes and then 
complementary deoxyribonucleic acid (cDNA) was synthesized using RT (reverse 
transcriptase)-PCR kits from Qiagen and Bio-Rad according to the manufacturer’s protocols. 
Quantitative gene expression was done by real-time PCR using a three-step PCR protocol and 
Bio-Rad CFX manager software (version 2.1, Bio-Rad, Hercules CA). The primers and 
probes for the experiment was designed with primer blast 
(www.ncbi.nlm.nih.gov/tools/primer-blast), and checked for specificity with melt-curve 
analysis. The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
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used to normalize the mRNA expression levels of the studied transcripts. Normalized 
expression levels were calculated with Bio- Rad CFX manager.  
3.11 NEUROIMAGING AND COGNITIVE MEASURES 
The regional cerebral glucose metabolism and the Aβ load in the brain were measured using 
18F-FDG-PET and 11C-PIB PET respectively in Study 1, which was done in the facilities at 
Nuclear Medicine and PET Center, University of Tuebingen, Tuebingen, Germany.  DatScan 
using SPECT was available for the DLB subjects in Study 3 and 4, which were performed at 
the respective centers belonging to DemVest and Trønderbrain study. 
Cognitive assessment was performed using MMSE, Boston Naming Test and other 
neuropsychological tests in all the studies.  
3.12 STATISTICAL ANALYSIS 
The statistical analyses were performed using Statview (SAS Institute Inc.) for all the studies. 
Additionally in the Study 3, the R-program for statistical computing was used.  
In Study 1, 2 and 4, the significance of results between the groups was analyzed using a 
analysis of variance (ANOVA, with a significance level chosen as of p< 0.05, and was 
followed with Fisher’s protected least significant difference post hoc analysis. Due to the 
small group size as well as the sensitivity of parametric tests to outliers, we double-checked 
the significant differences between the groups by both visual inspection and non-parametric 
Mann-Whitney tests. A two-tailed correlation z test (Statview) and nonparametric 
Spearman’s rank correlations were used for the correlation analyses, which were then 
visualized graphically using simple regression plot.  
In Study 3, Chi-square and Fisher exact tests were used to compare the genotype frequency 
and gender differences between the groups. The age, disease duration, and MMSE variable 
were compared between the groups using one-way ANOVA. Longitudinal analyses were 
performed with a linear mixed effects model, adjusting for covariates (age and gender) using 
R-program for statistical computing. A model with random intercept and slope, and 
Independently Identically Distributed (IID) residuals was used to produce a fit to the data. 
Further explorative analyses were performed using repeated-measures ANOVA.  
3.13 METHODOLOGICAL APPROACH 
The methodological approach for each study is represented as a flowchart in Figure 5 (Study 
1), Figure 6 (Study 2), Figure 7 (Study 3) and Figure 8 (Study 4) 
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Figure 5. Methodological approach in Study 1 
 
 
 
Figure 6. Methodological approach in Study 2.  
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Figure 7. Methodological approach in Study  
 
 
 
 
Figure 8. Methodological approach in Study 4.  
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4 RESULTS AND DISCUSSION 
This section of the thesis highlights the most important findings from Studies 1, 2, 3 and 4. 
Please refer to the study papers for details on all findings. 
4.1 EVIDENCE OF EXTRACELLULAR CHAT 
About a century of research in the cholinergic field has implied that ChAT is solely a 
cytosolic enzyme of the cholinergic neurons. However, from our Study 2, we found that, 
apart from being an intracellular enzyme, ChAT also exists extracellularly in CSF and 
plasma. We also showed that it is not only expressed but actively secreted by various cells, 
such as human embryonic stem cells, human primary astrocytes and mouse lymphocytes. 
This study, for the first time evinces astrocytes as cholinergic cells. 
The dot-blot analysis with different specific antibodies for human ChAT, provided 
compelling evidence for the presence of ChAT in CSF, plasma and brain homogenate (BH) 
(Figure 9a, b). We further performed western blot analyses and confirmed the presence of 
soluble ChAT. These analyses also revealed for the first time that ChAT may exist as various 
molecular forms, most likely composed by assembly of its monomeric globular subunit (G1) 
in a similar fashion to its counterpart enzymes, ChEs in CSF, plasma and brain homogenate 
(Figure 9c). Using the sedimentation analysis technique, we were able to confirm this and 
further characterize the different molecular forms of ChAT in CSF as G1, G2, and G4 with 
the corresponding molecular weights of 50–70 kDa, 100–140 kDa and 200–300 kDa, 
respectively (Figure 9h).  
We then developed a new sensitive, non-radioactive, simple and integrated ChAT assay, 
which sequentially measures first the activity and then the protein level of the enzyme 
(Figure 10). The assay results showed that plasma had about 50 fold higher ChAT than CSF 
and BH (Figure 10a, b).  
The stimulation experiment on mouse lymphocytes and human primary astrocytes showed 
that levels of ChAT protein secreted into the culture medium increases when activated 
(Figure 10c). This suggests that soluble ChAT might be required for in situ synthesis of ACh 
in extracellular fluid, and thereby for autocrine and/or paracrine ACh signaling.  
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Figure 9. Detection and characterization of extracellular ChAT protein in human 
plasma and CSF. (a) Dot-blot analysis of nine different pooled CSF samples using two different 
antibodies. (b) The relative amount of ChAT in plasma or CSF, compared to brain homogenates (BH) 
of AD or control. At 16-fold dilutions, the immunosignals are much stronger in plasma and CSF 
compared to BH. This demonstrates the relative abundance of the ChAT protein in extracellular 
fluids. (c) Western-blot characterization of molecular form of ChAT in plasma, CSF and BH. The 
major detected protein band (*) in the BHs corresponds to a ChAT protein with a Mw of 65 kDa. In 
addition, there are several detected heavier molecular forms of ChAT in the CSF. All samples were 
loaded on one gel. Note also that the amount of the,65 kDa ChAT was so high in plasma that it 
distorted the gel downward. (d–g) Combinatorial sandwich ELISA results for identification of 
extracellular ChAT using three different antibody pairs for recombinant human ChAT (rhChAT), and 
a pooled plasma sample (g) calibrated for ChAT protein concentration using the rhChAT and ELISA 
setup in (f). (h) Further characterization of the molecular forms of CSF ChAT in consecutive fractions 
of pooled AD CSF samples separated by sucrose-density gradient technique, and the subsequent 
quantification of ChAT by sandwich ELISA. The graph represents the average of nine different 
pooled CSF. This independent analysis provides an identical pattern of molecular forms detected by 
Western analysis. Due to lack of prior reports, we used analogous terminology, which is used for the 
counteracting cholinergic enzymes, AChE and BuChE, that is, Gn, where n denotes the number of 
globular subunits in each detected molecular form of ChAT in CSF. The molecular weights are 
calculated based on the known Mw of two internal standard proteins. In all dot-blot analyses, 2 mL of 
each sample (neat or diluted) was used. In the Western blot analysis, each lane was loaded with 15 
mL of a mixture, containing 10 mL of sample (neat or diluted) and 5 mL of a 6x concentrated 
reducing Laemmli loading buffer. All ChAT protein quantifications were done with the ELISA 
antibody pair’s combination in (g). Anti-ChAT antibodies: RP=rabbit polyclonal antibody (Ab), 
BGP=biotin-labeled goat polyclonal Ab, MAB=mouse monoclonal Ab. 
 
4.2 MAINTENANCE OF ACH EQUILIBRIUM BY EXTRACELLULAR CHAT 
Acetylcholine is an anti-inflammatory signaling substance that may regulate activity of 
various immune cells. However, this hypothesis poses a dilemma since ACh is a very 
unstable molecule and thereby very unlikely to be effective over long-distances. Our finding 
of extracellular ChAT in Study 2 provides a plausible explanation and evidence for this 
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missing link of such long-distant action of ACh in the cholinergic anti-inflammatory pathway 
of central and peripheral nervous system.  
The immunocytochemistry results from the stimulation experiment on the activated mouse 
lymphocytes added further evidence that ChAT rather than ACh is secreted by these cells. 
We hypothesized that the function of soluble ChAT is to maintain the equilibrium level of 
extracellular ACh, by continually resynthesizing ACh in situ, allowing ACh to have a tuned 
immuno-modulatory function, e.g., on functional status of lymphocytes and other 
cholinoceptive cells such as astrocytes. 
This hypothesis also allows us to explain another observation reported by us. Namely, in our 
recent study [69] we had shown that in AD CSF, Aβ peptides along with ApoE interacts  
 
Figure 10. The extracellular ChAT protein is functionally intact and physiologically balanced in 
both plasma and CSF. (a–b) The quantity of the ChAT protein determined by ELISA in pooled brain 
homogenates of control brains (Ctrl BH) and AD brains (AD BH), AD CSF and plasma. The 
concentration of ChAT in the plasma is 50-fold higher (b) than the CSF samples (a). (c) The amount 
of ChAT in the cell-culture medium of human embryonic stem cells (hES) and human brain primary 
astrocytes, indicating that these cells readily released ChAT into the medium. (d–e) illustrate , 300-
fold higher overall activity of the counteracting enzymes, red blood-cell acetylcholinesterase (RBC-
AChE), and plasma BuChE (d) compared to the AChE and BuChE activities in the CSF (e). These 
observations may suggest that ChAT levels in plasma and CSF (a–b) is balanced to the corresponding 
physiological levels of AChE and BuChE activities. (f) The amount of ChAT normalized to the total 
protein in the samples. (g–h) Two new, alternative, colorimetric assays of ChAT activity confirmed 
that the plasma and CSF ChAT are functionally intact. ChAT activity was measured directly (g) or 
after immunocapturing of the ChAT protein (h) into wells of microtiter plates coated with mouse 
monoclonal anti-ChAT antibody in a functional ELISA setup. (i) Comparison of measured ChAT 
activity by these two approaches, indicating that both approaches provide essentially similar levels of 
ChAT activity in pooled plasma samples. The functional assay also excludes any possible contribution 
or interference of other plasma constituents in the synthesis of acetylcholine (e.g., by carnitine 
acetyltransferase), since ChAT protein is first immunoadsorbed and the other plasma constituents are 
washed away before the substrates and other necessary reagents are added. (j–l) The plasma, CSF and 
brain ChAT activities normalized to quantify ChAT protein or the total protein in the samples. The 
digits in the column bar represent the number of samples that were analyzed. 
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with AChE and BuChE leading to the formation of high molecular weight BuChE/AChE-Aβ-
ApoE (BAβA) complexes. These BAβACs contain hyperactive ChEs, which readily degrades 
ACh in the extracellular compartments. Our finding of the extracellular presence of ChAT 
helps to understand the equilibrating mechanism involved with this depletion in the level of 
ACh. This way, we proposed a native biological function for Aβ peptides. In other words, by 
Aβ release and reuptake, cells can shift the extracellular ACh equilibrium to low and high 
levels, respectively. Thus Aβ, through BAβACs, may function as a modulator of ACh 
signaling.  
To provide some evidence for this hypothesis, we designed an ACh equilibrium assay and 
showed the maintenance of ACh equilibrium by ChAT in the presence of fully active and 
naturally occurring amounts of the ACh degrading enzymes, AChE and BuChE at both room 
temperature (where ChAT is sub-optimally active) and 38°C (at which ChAT is fully active 
(Figure 11).  
 
Figure 11. Extracellular CSF ChAT proteins maintain a steady- state level of ACh in the 
presence of naturally occurring levels of fully active cholinesterases. (a) Schematic illustration of 
the overall reaction setup. Pooled CSF sample was incubated for one hour with a cocktail containing 
10 mM choline chloride and 50 mM acetyl- Coenzyme A (Acetyl-CoA). To avoid depletion of 
Acetyl-CoA, the accessory enzyme phosphotransacetylase (PTA) and acetyl-phosphate (A-Ph) were 
included in the cocktail to continuously regenerate the required cofactor, Acetyl-CoA. It should be 
noted that this setup allows an equilibrium between synthesis and degradation of ACh be reached (b) 
CSF ChAT maintains a steady-state ACh concentration of 2.11±0.27 mM after one hour at room 
temperature. However, ChAT becomes fully activated at 38uC. This is shown in panel (c), 
corresponding to a steady-state ACh concentration of 3.43±0.14 mM. No inhibitor of AChE or BuChE 
was used providing strong evidence that the ACh-synthesis by ChAT produces an ACh equilibrium 
level in the presence of naturally occurring amount of these ACh-hydrolyzing enzymes in CSF. 
**p<0.0013 compared to ACh level generated at the room temperature. 
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4.3 HIGH CSF APOE LEVELS IN APOE4 CARRIERS AND DEMENTIA 
PATIENTS 
Several years of dementia research have shown a close association of APOE4 with the 
pathophysiological alterations in AD and other types of dementia such as DLB and PDD. In 
accordance with the previous studies, [16, 101, 102], the AD and DLB groups in our Study 1 
and 4 had higher number of APOE4 carriers than the non-demented groups and controls.  
In agreement with our previous observations [58, 69], we found a higher level of CSF ApoE  
in APOE4 carriers than in non-carriers. This was confirmed in both Study 1 and Study 4, 
which included patient cohorts from two independent study groups belonging to two different 
geographic regions, namely Germany and Norway, respectively (Figure 12a, 13a). ApoE 
protein serves as a receptor ligand for the low-density lipoprotein receptor and its related 
receptors, which are abundantly expressed in CNS by neurons. Thus, ApoE putatively 
mediates the transport, redistribution, and metabolism of cholesterol and other molecules in 
the brain, which has a high lipid turnover [103].  
A plausible explanation for higher CSF levels of ApoE protein in APOE4 carriers than non-
carriers could be that a larger number of ApoE4 molecules are needed to generate similar-size 
lipid particles compared to ApoE3 isoprotein [104]. This suggests that astrocytes and glial 
cells in the brain of APOE4 carriers have to express more ApoE protein to maintain a similar 
supply of cholesterol to neurons as occurs  in APOE4 non-carriers.  
Nonetheless, the studies regarding the ApoE levels in CSF (and plasma) of APOE4 carriers 
and non-carriers have shown contradictory results, with some reports showing high CSF 
ApoE levels [58, 69, 105, 106] and others showing low levels in CSF [107, 108] and brain 
[109] of APOE4 AD patients .  
However, it should be noted that disregarding APOE genotype, we observed a trend of higher 
CSF ApoE level in the dementia patients (DLB and PDD compared to the non-demented 
patients PDND and Controls) in Study1 (Figure 12b). This suggests that high ApoE protein 
level may be involved in evolution of dementia, in particular in the presence of APOE4 
genotype, with a high protein expression rate as a causative factor, for not only AD but also 
for DLB and PDD.  
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Figure 12. High cerebrospinal fluid (CSF) apolipoprotein E (apoE) protein level in patients who 
areAPOEε4 positive and who have dementia. (a) The apoE protein levels in the CSF of APOE ε4 
carriers shows twofold higher levels than the CSF of APOE ε4 non-carriers. (b) Patients with 
dementia with Lewy bodies (DLB) have the highest CSF ApoE level compared with other dementia 
groups, regardless of their APOE genotype. ***P<0.001 indicates the difference between APOE ε4-
positive and -negative groups. #P<0.06 indicates a trend of difference between patients with DLB and 
healthy control subjects (HCs) Digits indicate the number of subjects in each group. Data are 
presented as a percentage of HCs and standard error of the mean.  
 
 
 
Figure 13. Apolipoprotein E (ApoE) levels in CSF of dementia (AD and DLB) patients and 
controls based on their APOE4 and BCHE-K genotype. (a) ApoE protein level based on number 
of APOE4 carriers in dementia patients and controls. ε4=0, ε4=1, ε4=2 represents the number of ε4 
allele. Data are presented as percentage of ε4-noncarriers (ε4=0). **p<0.01 and *p<0.05 signify 
differences between ε4=0 and ε4=2, ε4=1 respectively. (b) ApoE protein level based on combined 
APOE4 and BCHE-K genotypes in dementia patients, and controls. ε4+K+ - patients with both APOE4 
and BCHE-K genotypes, ε4+K- - patients with APOE4 but not BCHE-K, ε4-K+ - patients with BCHE-
K but not APOE4, ε4-K- - patients without APOE4 and BCHE-K. The data are presented as percentage 
of ε4-K+. **p<0.01 and *p<0.05 denote the significant differences between ε4-K+ and ε4+K+, ε4+K- 
respectively. Digits in the bars indicate the number of subjects in each group. Values are given as 
standard error of the mean. The APOE4 and BCHE-K genotypes were not available for the control 
group.  
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4.4 ROLE OF APOE4 AND BCHE-K GENOTYPES 
While APOE4 genotype seems to be associated with high CSF ApoE ([69] and our findings), 
BCHE-K is associated with low BuChE activity in serum and CSF of AD and DLB patients 
[58, 110]. Consistent with these previous findings, we found that there was a significant dose 
dependent increase in CSF ApoE levels (Figure 13.a) and a trend of low BuChE activity in 
CSF of BCHE-K carriers than non-carriers (Figure 14.a) (Study4)  
 
Figure 14. Butyrylcholinesterase (BuChE) activity in CSF of dementia patients (AD and DLB) 
and controls based on their APOE4 and BCHE-K genotype. (a) BuChE activity in BCHE-K 
carriers and noncarriers in dementia patients and controls. The data are represented as percentage of 
K-noncarriers. #p<0.09 represents a trend in difference between BCHE-K carriers and non-carriers (b) 
BuChE activity based on combined APOE4 and BCHE-K genotype in dementia patients and controls. 
ε4+K+ - patients with both APOE4 and BCHE-K genotypes, ε4+K- - patients with APOE4 but not 
BCHE-K, ε4-K+ - patients with BCHE-K but not APOE4, ε4-K- - patients without APOE4 and BCHE-
K. Data are represented as percentage of ε4-K+. *p<0.05 and #p<0.1 represents the significant 
difference and a trend in difference between ε4-K+ and ε4-K-, ε4+K- respectively. Digits in bars indicate 
the number of subjects in each group. Values are given as standard error of the mean. The APOE4 and 
BCHE-K genotypes were not available for the control group.  
 
BCHE-K frequency was significantly lower in DLB patients (33.9%; p<0.01) than control 
subjects (51.2%), and numerically lower in AD than controls (38.9%; p=0.11) (Study 3). The 
rate of cognitive decline was significantly higher (p=0.037) in APOE4 carriers than non-
carriers, but there was no-significant difference between BCHE-K carriers and non-carriers 
during the five-year follow up period.  
In Study 3, we further explored the association of APOE4 and BCHE-K genotype with 
cognition in AD and DLB patients. Using repeated measures ANOVA, we found that APOE4 
non-carrier|BCHE-K carrier (ε4-K+) patients had a significantly slower annual decline in 
global cognition, assessed by MMSE test compared to those with both APOE4 and BCHE-K 
genotype (ε4+K+) (Figure 15) 
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Figure 15. Cognitive decline in all AD and DLB patients based on their Apolipoprotein E ε4 
(APOE4) and Butyrylcholinesterase K (BCHE-K) genotypes. All AD and DLB patients from the 
DemVest study are divided into four groups based on their APOE4 and BCHE-K genotypes. The lines 
show the mean MMSE test score in each group during the five-year follow up period. The digits in the 
parenthesis indicate the number of individuals in the corresponding group. Only patients with all 
MMSE test assessment data for the five years of follow-up were included in this analysis using 
repeated measures ANOVA. The patients were grouped based on the combination of APOE4 and 
BCHE-K genotypes. The analysis indicated a significant interaction between MMSE and the APOE4 
and BCHE-K genotypes (p<0.05).  
 
The outcome of APOE4 and BCHE-K genotype (alone or combined) has been investigated in 
several studies in AD and DLB with contradictory findings [111-115]. We did not observe 
any association of a slower cognitive decline with BCHE-K variant (alone, regardless of 
APOE genotype), although this has been previously reported in a mixed cohort of DLB and 
AD [116] and a large AD cohort [117]. However, in a study of patients with PD dementia, 
those with a combination of both APOE4 and BCHE-K had a significantly more rapid 
cognitive decline than the groups with either APOE4 or BCHE-K [118] indicating a potential 
interaction between the two genotypes. However, in our study in presence of APOE4, the 
BCHE-K genotype did not significantly altered the main effect of APOE4 on the annual rate 
of cognitive decline in the patients, although at the fifth year of follow-up the ε4+K+ exhibited 
divergent rate from the other groups (Figure 15). 
Noteworthy, the APOE4 non-carrier|BCHE-K carrier patients in our study also exhibited 
lowest ApoE protein (Figure 13b) and BuChE activity levels (Figure 14b) in CSF compared 
to those who were carriers of both. This might suggest a protective effect of BCHE-K 
genotype through a combination effect on reduced BuChE activity (i. e. high ACh 
availability) and lowering ApoE protein expression. In support of this notion, a very recent 
study show that ApoE protein, in particular the ApoE4 isoprotein stimulates neuronal Aβ 
production [119] thus explaining the risk of AD by ApoE4.  
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In contrast, in the presence of APOE4 genotype, most likely due to high ApoE protein 
expression, the protective effect of the BCHE-K genotype may not be enough to compensate. 
It is also evident from our previous studies that APOE4 genotype through its high protein 
expression can modulate the phenotypic expression of BuChE protein in CSF of AD patients.  
4.5 ASSOCIATION OF APOE AND BUCHE WITH OTHER AD MARKERS 
The ApoE and BuChE levels in the CSF showed significant associations with the AD 
markers such as Aβ, Tau and sAPP.  
In Study 1, high CSF ApoE levels were negatively associated with cognitive measures 
(MMSE and Boston naming tests) and cerebral glucose metabolism (18F FDG-PET), CSF 
Aβ42 levels and AChE R/S ratio but positively with Aβ load in the brain (11C PIB-PET) and 
CSF T-Tau, sAPPα and sAPPβ levels. In Study 4, once more CSF ApoE levels exhibited 
positive associations with Tau, sAPPα, sAPPβ and sAPPβ/α ratio in CSF (Table 6), strongly 
supporting the findings observed in Study1.   
Reports indicate that APOE4-carriers exhibit accelerated age-related changes in cortical 
thickness and hippocampal volume, which seem to be related to the cognitive performance of 
patients. There are also numerous studies reporting low glucose metabolism in APOE4 
carriers than non-carriers, especially among AD patients. Hence, the association of high CSF 
ApoE levels due to APOE4 genotype with the cognitive measures and glucose metabolism in 
our studies are also in line with these previous observations.  
Hence, ApoE protein, and in particular the ε4 isoprotein may exert multiple roles in the 
pathological mechanism in dementia such as neuronal integrity, synaptogenesis and 
neurodegeneration as well as directly affecting neuronal Aβ production and release [119]. In 
addition, recent findings from our group have shown that ApoE protein prevents Aβ 
fibrillization in an isoform and concentration dependent manner [72].  
In this context, we also found a consistent pattern of association between CSF ApoE and 
BuChE (overall activity, and the total and functional protein levels) (Figure 16).  Moreover, 
the BuChE activity and protein levels also showed a similar pattern of association with the 
CSF AD biomarkers, as was found for CSF ApoE (Table 5). Overall what we observed in 
Studies 1 and 4 are in-line with genotypic interaction between APOE and BCHE discussed in 
Study 3. Another interesting biological link between ApoE and BuChE is that astrocytes are 
the source of both proteins. The astrocytes are a key regulator of the immune response in the 
brain, and the association between ApoE and BuChE could reflect their role in 
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neuroinflammation in dementia. Apart from this, both ApoE and BuChE seem to co-occur in 
Aβ plaques and neurofibrillary tangles further supporting the findings in the Studies 1, 2 and 
4). The association of ApoE and BuChE with sAPPα and sAPPβ levels in Study 4 (Table 5) 
suggests a possible role of ApoE and BuChE not only in Aβ clearance and aggregation, but 
also in APP processing mechanism. Hence the association of ApoE with BuChE, Aβ and 
sAPP is very interesting and strongly warrants further mechanistic studies. 
 
Figure 16. High Apolipoprotein E (ApoE) levels in cerebrospinal fluid of dementia patients (AD 
and DLB) patients is associated with high butyrylcholinesterase (BuChE) levels.  In the CSF of 
dementia patients, the ApoE levels shows positive correlation with (a) functional BuChE protein 
(p<0.05), (b) total BuChE protein (p<0.05) and (c) with BuChE activity levels (p<0.06). In contrast in 
the control subjects, the pattern of association between ApoE and BuChE level was reversed, 
although statistically not significant [(a) BuChE functional protein (p<0.3); (b) BuChE Total protein 
(p<0.4) and (c) BuChE activity (p<0.3)]. 
 
4.6 HYPOTHETICAL MECHANISM OF PHYSIOLOGICAL AND 
PATHOLOGICAL ACETYLCHOLINE SIGNALING  
Several previous studies by us and others, have revealed new views on possible mechanism 
of action and consequences of the molecular interaction between ApoE, BuChE, AChE and 
Aβ, the formation of BAβACs, and its role in regulation of the function of astroglial cells. 
This hypothesis like the well-established cholinergic anti-inflammatory hypothesis was 
suffering from the fact that ACh is an extremely instable signaling molecule in extracellular 
fluids.  The investigation on the existence of extracellular ChAT was hence undertaken as a 
proof-of-concept in support of this hypothesis (Figure 17). This hypothesis is elaborated 
schematically by the Figure 17.  
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Figure 17. Hypothetical pathway for regulation of non-excitable cholinoceptive cells through 
distant action of extrasynaptic ACh. Extrasynaptic ACh can exert long distant regulatory effects on 
non-excitable cholinoceptive cells, such as microglia, astrocytes, oligodendrocytes and endothelia, 
mediated mainly through activation of nicotinic α7-ACh receptors. However, extracellular ACh is 
highly labile due to extracellular presence of the ACh-degrading enzymes, AChE and BuChE. (1) The 
finding here of presence of extracellular ACh-synthesizing enzyme, ChAT, proposes a model in which 
continuous synthesis of ACh counteracted by breakdown could maintain a steady-state equilibrium, 
which can regulate glial activation status. (2) This equilibrium may also be influenced by neuronal 
activity, since action potentials by cholinergic neurons, for example, may lead to synchronized 
production and release of Aβ peptides into the interstitial fluid. (3) These Aβ peptides can interact 
with AChE and BuChE, and temporarily form BAβA-complexes (BAβACs), in which these enzymes 
acquire ultrafast catalytic activity, plausibly through induction of certain conformational change in 
their tertiary structures. (4) The hyperfunctional BAβACs will then effectively shift the equilibrium 
state towards lower ACh, which in turn leads to the activation of glia with expression of, for example, 
complement factors. (5) Reuptake of Aβ peptides will result in disintegration of BAβACs, (6) 
normalization of the steady-state balance, and (7) the initial astroglial status. (8) In AD the presence of 
the apolipoprotein E ε4 allele (APOE4) genotype may disturb the balance additionally due to 
dysfunctional Aβ re-uptake (clearance) and/or high levels of ApoE protein, a common condition 
among APOE4 carriers. High ApoE protein will prolong the interaction between cholinesterases and 
Aβ, leading to gradual accumulation and deposition of BAβACs in the brain. (9) BCHE-K genotype 
with its low BuChE activity and BCHE-Wt with its high activity leads to high ACh and low ACh 
levels in extracellular compartments thereby regulating ChAT (10) APOE4 triggered high ApoE 
protein expression causes a phenotypic modulation of BuChE protein isoforms leading to high BuChE 
activity in the BAβACs. The end stage, BAβACs is deposited together with Aβ peptides in the brain 
as parts of the Aβ plaques and cerebral amyloid angiopathies, two hallmarks of Alzheimer’s disease 
brain, which also explains the documented presence of BuChE, AChE and ApoE in these Aβ deposits. 
 
In another study, which is not included in this thesis, we challenged the modulatory action of 
Aβ peptides on the extrasynaptic ACh signaling using neurospheres derived from human 
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embryonic stem cells, which we treated for 26 days with oligomeric and fibrillar Aβ 
preparations. One of the most striking finding in this experiment was that fibrillar, but not 
oligomeric Aβ, altered the release and activity of ChAT and BuChE by these cells, favoring a 
hypocholinergic microenvironment in the culture medium of these cells. This seemed in turn 
to favor the differentiation of the neurospheres’ cells toward gliogenesis (Figure 18).  This 
finding hence strongly supports the notion of a close interplay between Aβ peptides and 
cholinergic signaling [120]. 
 
 
Figure 18. Treatment of neurospheres with fibrillar preparation Aβ peptides decreases ChAT 
protein expression and increases BuChE activity and protein expression. Neurospheres derived 
from human embryonic stem (hES) cells (a) were differentiated for 11 days in vitro (DIV) and 
subsequently treated once a week with different concentrations of fibrillar Aβ (fAβ). The condition cell 
media was collected and the protein level of ChAT (b), and BuChE activity (c) was measured at 4 
different time-points (11-26 DIV) using ChAT specific sandwich ELISA and BuChE activity assay. 
The treated and un-treated cells were also assayed by immunocytochemistry for expression of neuronal 
marker (BIII-tubulin, red color), and the glial marker, glial fibrillary acidic protein (GFAP, green 
color). *p<0.05, **p<0.01 and ***p<0.001 indicates the significant difference between the DIV. The 
values are normalized to baseline at DIV11 and given as mean ±SEM.  (The figure is modified from 
Malmsten et al, Journal of cellular and molecular medicine). 
 
Another line of supportive evidence for the function of soluble ChAT comes from the finding 
that the levels of soluble ChAT in CSF were balanced by the expected reduction in the 
BuChE by BCHE-K genotype. In other words, we found that lower BuChE activity of the K 
variant protein compared to the wildtype was balanced in K-gene dosage dependent manner 
by a lower ChAT levels in CSF of K carriers compared to the CSF of the wild-type BCHE 
carrier AD patients (Study 2). This might mean that the maintenance of extrasynaptic ACh 
level in subjects with low BuChE activity due to BCHE-K demands lower level of soluble 
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ChAT compared with relatively higher ACh-degrading BuChE activity due to wildtype 
BuChE protein variants.  
This hypothetical scenario might prevail as long as ApoE protein levels and/or Aβ release and 
reuptake are physiologically normal, but is disrupted in pathological conditions due to for 
instance, abnormal ApoE protein expression by an aberrant expression of APOE gene, either 
duo to ε4 allele or hypocholesteremia.  
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Table 5. Associations of Apolipoprotein E and Butyrylcholinesterase with other Alzheimer’s disease markers in Cerebrospinal fluid. 
CORRELATIONS 
CSF 
MARKERS 
ApoE BuChE Activity BuChE Total protein BuChE Functional protein 
 
Dementia Controls Dementia Controls Dementia Controls Dementia Controls 
 
r p r p r p r p r p r p r p r p 
sAPPα 0.41 ***0.001 -0.58 0.55 0.17 0.38 0.05 0.84 0.19 0.27  -0.06 0.92 0.20 0.28 0.14 0.55 
sAPPβ 0.20 #0.06  -0.55 0.32 0.12 0.61 -0.11 0.55 0.13 0.41 -0.22 0.76 0.12 0.54 -0.05 0.84 
sAPPβ/sAPPα -0.46 ***0.001 0.17 0.84 -0.05 0.60 -0.35 0.69 -0.08 0.57 -0.33 0.76 -0.11 0.42 -0.40 0.23 
Ab42/Ab38 -0.32 *0.03 0.05 0.85 -0.18 0.34  0.16 0.95 -0.17 0.32  0.33 0.90 -0.17 0.30 0.14 0.65 
T-Tau 0.43 ***0.001 0.98 #0.07 0.29 #0.08  -0.62 0.16 0.29 *0.04 -0.63 0.26 0.28 #0.06 -0.55 0.23 
p-Tau 0.45 ***0.001 0.31 0.55 0.23 #0.06 0.42 0.42 0.21 *0.04 0.53 0.26 0.24 *0.05 0.34 0.55 
Ab42/ T-Tau -0.36 **0.01 -0.39 0.69 -0.23 0.1 0.83 0.84 -0.21 #0.08 0.90 0.68 -0.20 #0.08  0.74 0.55 
Ab42/p-Tau -0.31 **0.01 0.45 0.23 -0.16 #0.08  0.05 0.55 -0.11 0.1 0.05 0.68 -0.14 #0.06 0.11 0.84 
 
***p<0.001, **p<0.01, *p<0.05 represents the significance in correlations. #p represents the trend in correlations based on Spearman rank correlations. 
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5 LIMITATIONS  
The major limitation in our Studies 1 and 4 are that the patient cohorts were relatively small 
and hence larger sample size in each group is needed to confirm results from these studies. 
The small sample size might also be the reason why some statistical tests showed (only) 
borderline-significant results, which may fail in a more rigorous post hoc correction for 
multiple comparisons.  
All the patients from the DemVest study (Study 3 and 4), Trønderbrain study (Study 3) and 
from Tuebingen hospital (Study 1) were those coming to the clinics for routine diagnosis and 
hence some of them were undergoing treatment with ChEIs, L-Dopa and other medications. 
Therefore, the observations from these studies should be interpreted with caution. Despite the 
possibility for confounding effects of such medications, the core findings could be confirmed 
between the studies with reasonable certainty, since the pattern of the observations were in-
line with previous reports in other studies on AD and DLB patients by us and others.  
The diagnoses of the patients were based on their clinical assessment. Most of the DLB 
subjects in Study 3 and 4 had AD-type pathology. Hence there could be a chance of 
misdiagnosis especially for DLB as AD. Although, the findings in Study 3 were adjusted for 
the effect of age and gender, the observations from other Studies were not adjusted for these 
covariates due to small sample size. 
Study 2 is the only study reporting the presence of extracellular ChAT and its role in 
maintaining ACh equilibrium. Although we made every possible challenge that we could 
think that might have biased the findings, all the evidences come from our group and hence 
need to be confirmed by others. Some of the findings in this study are based on pooled CSF, 
plasma and BH from AD and control patients, which aimed at addressing the presence of 
soluble ChAT. Analyses on individual samples were run in a small group of patients with 
multiple sclerosis and their matched controls as a challenge to possible involvement of 
soluble ChAT in inflammation. A reported study and several ongoing studies by our group 
are underway to address changes in the plasma and CSF of AD, DLB, PDD, MCI and SCI, 
before or following short- and long-term treatment with ChEIs. These studies should provide 
additional insight on the function of soluble ChAT and its suitability as a biomarker in 
dementia and or neuroinflammatory disorders.  
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6 CONCLUSION 
The findings in this thesis provide evidence from various angles for the presence of biological 
and molecular interaction between ApoE, cholinergic enzymes (ChEs, ChAT), and CSF AD 
biomarkers (Aβ, sAPP and Tau), as well as genotypic interaction between APOE4 and 
BCHE-K in dementia, especially in AD and DLB. This thesis also elucidates mechanistic 
information on a plausible mechanism behind the interference of ApoE with the extracellular 
function of BuChE and ChAT.  
With the findings from our all four studies we could draw the following conclusions.  
The results of two independent study cohorts (Studies 1 and 3) confirm that abnormally high 
level of ApoE in CSF is triggered by the APOE4 genotype, and may, hence, act as a driving 
force in the pathophysiological events of, not only AD but also the Lewy body associated 
dementia disorders (DLB and PDD). The results of Study 4 confirm the notion of molecular 
interaction between ApoE and cholinergic enzymes at the genetic level. 
The Study 2 in this thesis provides compelling evidences for the presence of high levels of 
ChAT in extracellular fluids, about a century after the discovery of this enzyme by 
Nachmansohn and Machado [49] This study also led to development of a novel high-
throughput quantitative assay for simultaneous measurement of ChAT activity and protein 
levels in practically any biological fluids. This assay allowed us to formulate, and challenge 
a new hypothesis about a possible function of soluble ChAT, viewed as a missing link for 
the well-established long distant hormone-like action of ACh. The study proved that CSF 
ChAT by continuous renewal of ACh could establish certain ACh equilibrium, despite the 
presence of the two fastest known ACh hydrolyzing enzymes, AChE and BuChE.  This 
study also for the first time showed that human primary astrocytes are not merely 
cholinoceptive (responsive to ACh), but also that they may acquire cholinergic phenotype 
on demand and release soluble ChAT. Moreover, this study showed that lymphocytes 
release ChAT rather than ACh, and that together with astrocytes may be the source of 
soluble ChAT in circulation and in CNS, respectively. 
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7 FUTURE PERSPECTIVES 
The studies included in this thesis demonstrate the importance of investigating the 
mechanism of interaction between ApoE, BuChE and ChAT in AD and DLB patients. 
Hence, findings warrant more future studies with large multi-centered patient cohorts to 
confirm and expand the findings. The measurements of ApoE, BuChE and ChAT in matched 
CSF and plasma from dementia patients and controls along with their APOE4 and BCHE-K 
genotype should enable deeper insights about their contribution in the pathology of dementia 
and especially in AD and DLB. Such studies, along with neuroimaging and clinical 
parameters, with multivariate analysis would point out new biomarkers and/or combination 
of biomarkers that could help in early diagnoses of asymptomatic patients, and can be for 
differential diagnosis and/or prognostic marker for AD and DLB (Figure 19). 
Figure 19. Schematic presentation of the possible multivariate analysis for a new 
differential and prognostic marker for AD and DLB  
APOE4 is the main confirmed genetic risk factor for sporadic AD, an understanding of the 
molecular mechanism concerning its abnormal levels in the brain, CSF and plasma, perhaps 
along with BuChE activity and protein levels may be fundamental and instrumental in the 
understanding the disease mechanism and development of effective therapeutic agents.  
Considering that, despite over three decades of intensive search for new therapeutic agents, 
and numerous failed clinical trials on agents targeting APP metabolism, Aβ aggregation, and 
deposition, the ChE Inhibitors are still the main therapeutic options for the symptomatic 
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treatment in AD, DLB and PDD, the proposed molecular interaction of ApoE with BuChE 
and Aβ might prove to be a more fruitful therapeutic target, in particular since it brings 
together several plausible and/or well documented phenomenon, such as dysfunctional Aβ 
production, accumulation and clearance, selective vulnerability of cholinergic neuronal 
networks and neuroinflammatory processes involving astroglial cells function that may be 
under regulation of ACh signaling. 
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